Diagnostic Center | April 05, 2024
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated
